Bactericidal activity and pharmacology of flucloxacillin.
Flucloxacillin, a recent addition to the group of isoxazolyl penicillins, was studied in vitro and in normal volunteers. The bactericidal activity of the drug against most strains of gram-positive bacteria including penicillin-resistant Staphylococcus aureus was similar to that of oxacillin and approximately fourfold greater than that of cloxacillin. Each of the three penicillins was administered orally to a group of ten volunteers for eight days in a dose of 500 mg four times a day. The mean concentrations of flucloxacillin in the serum were two- to sixfold higher than those of the other two agents on the first, fourth and eighth days of therapy. The percentage of flucloxacillin bound by serum protein was 94.6 per cent; for cloxacillin and oxacillin the values were 93.5 and 91.5 per cent, respectively. Using these data, the concentrations of free flucloxacillin in serum were found to be twice as high as those of cloxacillin and oxacillin. These findings suggest that, when administered orally, this new agent may offer some therapeutic advantage over oxacillin and cloxacillin.
D001798:Blood Proteins / Q000378:metabolism; D003023:Cloxacillin / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D003470:Culture Media; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology; D008297:Male; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000097:blood / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D011485:Protein Binding; D011513:Proteus mirabilis / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
D001798:Blood Proteins; D003470:Culture Media; D007555:Isoxazoles; D010406:Penicillins; D003023:Cloxacillin; D010068:Oxacillin